If prostate cancer cells grow rapidly in the spine because of the presence of growth factors in bone marrow, then why do the tumor cells tend to grow so slowly in the prostate? A possible explanation was offered by Mark Litwin, a surgical resident at the time who is now on the faculty of urology at UCLA medical school. Mark argued that the prostate might contain naturally occurring inhibitors of prostate cancer growth, and he showed that prostate extracts could inhibit the growth of cultured prostate cancer cells.
Purifying and identifying the factor was no easy task, since the inhibitor was a small molecule that contained no protein, lipid or carbohydrate.The job fell to postdoctoral fellow Roy Smith, who eventually identified it as spermine (NH2-CH2-CH2-CH2-NH-(CH2)4-NH-CH2-CH2-CH2-NH2). Spermine is a naturally occurring member of the polyamine family that is particularly abundant in the prostate. (Smith RC, Litwin M, Lu Y, Zetter BR. Identification of an endogenous inhibitor of human prostate carcinoma cell growth. Nature Medicine. 1995: 1:1040-1045.)
In a continuation of this work, Chieko Koike, a post-doctoral fellow, demonstrated a potential mechanism for spermine inhibition of prostate cancer cell growth. She showed that a protein called antizyme was induced by spermine in prostate cancer cells that were inhibited by spermine. She also found that some very aggressive, highly metastatic prostate cancer cells become resistant to spermine. In the resistant cells, no antizyme was induced by spermine treatment. These results suggest that the induction of antizyme by spermine treatment is responsible for the growth inhibitory effects of spermine on prostate cancer cells (Koike C, Chau DT, Zetter BR. Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res. 1999; 59:6109-6112).
|